iCAD To Report Second Quarter and Six Months Ended June 30, 2018 Financial Results On Tuesday, August 14TH
NASHUA, N.H. (August 7,
2018) – iCAD, Inc. (NASDAQ: ICAD), an industry-leading
provider of advanced image analysis, workflow solutions and radiation therapy
for the early identification and treatment of cancer, today announced that it will release financial
results for the second quarter and six months ended June 30, 2018 after the
close of the market, and host a conference call at 4:30pm Eastern Time, on Tuesday,
August 14th.
Tuesday,
August 14th @ 4:30pm Eastern Time
Domestic: 888-394-8218
International: 323-794-2588
Conference ID: 1225538
Webcast: http://public.viavid.com/index.php?id=130346
Replays,
available through August 28th:
Domestic: 844-512-2921
International: 412-317-6671
Replay
PIN: 1225538
In
addition, a replay of the call will remain on the Company’s website (www.icadmed.com)
until the Company releases its third quarter 2018 financial results.
About iCAD, Inc.
iCAD delivers innovative cancer detection and
radiation therapy solutions and services that enable clinicians to find and
treat cancers earlier and faster while improving patient outcomes. iCAD offers
a comprehensive range of upgradeable computer aided detection (CAD) and
workflow solutions to support rapid and accurate detection of breast and
colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®)
System® is a painless, non-invasive technology that delivers high dose rate,
low energy radiation, which targets cancer while minimizing exposure to
surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for
use anywhere in the body, including treatment of non-melanoma skin cancer,
early-stage breast cancer and gynecological cancers. The comprehensive iCAD
technology platforms include advanced hardware and software as well as
management services designed to support cancer detection and radiation therapy
treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
CONTACTS:
Media
Inquiries:
ARPR,
LLC
Erin
Bocherer
(855)
300-8209 x120
or
Investor
Relations:
LifeSci
Advisors
Jeremy
Feffer
(212)
915-2568